<DOC>
	<DOCNO>NCT02368314</DOCNO>
	<brief_summary>The purpose study prove equivalence efficacy safety BCD-080 Clexan deep vein thrombosis embolism prophylaxis orthopedic surgery .</brief_summary>
	<brief_title>A Safety Efficacy Study BCD-080 Compared Clexan Deep Vein Thrombosis Prophylaxis Orthopedic Surgeries</brief_title>
	<detailed_description>The study include 116 patient plan hip knee replacement . Patients randomize 2 group . 1-st group receive BCD-080 dose 30 mg every 12 hour 14 day surgery , 2-d group receive Clexane dose . Efficacy assessment include frequency deep vein thrombosis ( DVT ) ( proximal and/or distal ; symptomatic asymptomatic ) , symptomatic nonlethal thromboembolia pulmonary artery ( PATE ) venous thromboembolism death . Safety assessment include frequency `` big '' , `` small '' bleeding frequency heparin induce thrombocytopenia.The assessment efficacy safety parameter make treatment follow-up period ( till 60 day ) .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>1 . Written inform consent 2 . Age ≥18 year age ≤80 year 3 . Women body mass 50110kg , men body mass 57110 kg inclusive 4 . Patients plan hip knee replacement 5 . Willingness patient sex sexual partner preserve reproductive function use reliable method contraception , start screen 4 week last dose study drug . This requirement apply patient underwent surgical sterilization . Reliable method contraception involve 1barrier method combine one following : spermicides/oral contraceptive 6 . Ability patient , opinion investigator , meet Protocol requirement . 1 . Hypersensitivity component include formula preparation BCD080 ( CJSC BIOCAD ) Clexane ( SanofiAvensis France , France ) medication class 2 . Conditions diseases high risk bleeding : cerebral aneurysm aortic dissection , hemorrhagic stroke ( include history ) 3 . Intractable hemorrhage 4 . History documented disease blood coagulation ( hemophilia A B , Willebrand disease coagulopathies , idiopathic thrombocytopenic purpura , Heparin induce thrombocytopenia associate thrombosis without , thrombohemorrhagic syndrome , etc . ) anamnesis and/or moment examination 5 . Gastric duodenal ulcer erosive ulcerative lesion gastrointestinal tract 6 . Recent ischemic stroke 7 . Uncontrolled severe hypertension ; , case hypertension , blood pressure decrease achieve use combination 3 antihypertensive drug , compulsorily include diuretic , nondrug method correction ( saltfree diet , graduate exercise ) ; result two successive measurement supine arterial blood pressure interval 1530 minute , systolic blood pressure &gt; 180 mm Hg . diastolic blood pressure &gt; 105 mm Hg 8 . Diabetic hemorrhagic retinopathy 9 . Decompensated diabetes mellitus , diabetes mellitus complication 10 . Recent delivery ( last 90 day ) 11 . Bacterial endocarditis ( acute subacute ) 12 . Pericarditis pericardial effusion 13 . Renal and/or hepatic insufficiency 14 . Intrauterine contraception 15 . Surgeries injuries brain/spinal cord , spine , eye , major surgery injury within 90 day prior randomization ) 16 . Spinal surgery deformation history patient plan epidural/spinal anesthesia 17 . Active liver diseases 18 . Anamnestic information alcoholism , addiction drug abuse last year 19 . Contraindications surgeries 20 . Hemoglobin &lt; 100 g/l 21 . Platelet count &lt; 100х10*9/l 22 . Creatine clearance &lt; 30 ml/min 23 . Biochemical blood assay index : AST/ALT &gt; UNLх3 ; total bilirubin &gt; UNLх1,5 ( unless causal factor provide , Gilbert 's syndrome ) 24 . Necessity continue treatment anticoagulant ( except plan study ) , antiaggregant fibrinolytics ( eg , patient artificial cardiac valve , atrial fibrillation patient receive warfarin , etc . ) 25 . The use dextrans fibrinolytic therapy drug affect hemostasis ; 26 . Necessity use systemic glucocorticosteroids nonsteroidal antiinflammatory drug ( except use latter purpose anaesthesia early postoperative period 3 day plan hip knee replacement ) 27 . Impossibility contrast venography : contrast allergy , inability install intravenous catheter , etc 28 . Pregnancy , lactation period 29 . Donation 450 ml blood plasma within 60 calendar day inclusion enrolment 30 . Participation clinical trial le 30 day enrolment study previous participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Deep vein thrombosis</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Sodium enoxaparin</keyword>
</DOC>